Unity Biotechnology snags $55 mln Series C
Unity Biotechnology Inc, a developer of treatments that prevent, halt, or reverse numerous diseases of aging, has raised $55 million in Series C financing. The investors included EcoR1 Capital Fund, 6 Dimensions Capital, Altitude Life Science Ventures, Fidelity Management & Research Company, Baillie Gifford, Partner Fund Management, Pivotal Alpha Limited, Invus Opportunities, ARCH Venture Partners, Venrock, Founders Fund and the Longevity Fund.
19 March 2018•1 min read
